CD86 and B-cell chronic lymphocytic leukemia: We recently analyzed the relationship between CLL EBV+ and CVID EBV− patients, which showed a significant advantage of CD4+ PD-1 and CD8+ PD-1 (Figure 11C); CD19+ CTLA-4+ and CD19+ CD86+ (Figure 12C); and all serum concentrations of the molecules tested except for sCD200 (Figure 14C).